SkinBioTherapeutics (GB:SBTX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SkinBioTherapeutics plc has achieved remarkable growth through strategic acquisitions and expanding its product lineup, resulting in a projected turnover of £6.3 million for FY25. The company has successfully extended its Croda partnership and launched new products in Europe, bolstering its presence in the skin health market. With these developments, SkinBioTherapeutics anticipates becoming cash flow positive by FY25, minimizing the need for further fundraising.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
